Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Holding HUMA?
Track your performance easily
HUMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.08 - $9.97
Previous Close$5.78
Volume6.30M
Average Volume (3M)2.96M
Market Cap
$658.60M
Enterprise Value$643.04M
Total Cash (Recent Filing)$93.56M
Total Debt (Recent Filing)$78.00M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 21, 2025EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding119,351,122
10 Day Avg. Volume3,079,411
30 Day Avg. Volume2,963,666
Standard Deviation0.30
R-Squared0.06
Alpha0.00028
Financial Highlights & Ratios
Price to Book (P/B)-24.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.05
Forecast
1Y Price Target
$13.00Price Target Upside124.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Humacyte News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyHumacyte's potential to make history with ATEV is underappreciated, with impressive clinical results such as a 90% 30-day patency rate and lower rates of amputation and infection compared to prosthetic grafts.
Market PotentialATEV's potential to serve an unmet need in AV access bolsters confidence that HUMA can penetrate this opportunity once approval is received.
Regulatory ProgressThe ATEV has FDA Fast Track designation, which supports expectations for FDA approval for use in vascular trauma repair.
Bears Say
Adverse EventsHigher adverse event rates observed for ATEV in the analysis, with thrombosis being the largest area of difference in adverse events.
Infection And Functional DeclineThere is a higher risk of infection and thrombosis with AVGs, and there is also a quicker functional decline compared to AVF.
Product HandlingHandling issues by surgeons who are more familiar with stiff PTFE grafts compared to HUMA's softer device may have contributed to the thrombosis rate.
---
Ownership Overview
8.49% Insiders
6.15% Mutual Funds
0.45% Other Institutional Investors
73.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $2.08 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Currently, no data Available
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Mar 21, 2025 which is in 131 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Nov 08, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.249 by -$0.081.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -$0.24.
How many shares outstanding does Humacyte have?
Humacyte has 125,209,050 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.249. Following the earnings report the stock price went up 9.886%.
Which hedge fund is a major shareholder of Humacyte?
Among the largest hedge funds holding Humacyte’s share is Deerfield Management Company, LP. It holds Humacyte’s shares valued at 2M.
---
Humacyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (124.91% Upside)
$13.00 (124.91% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 139.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.92%
12-Months-Change
Fundamentals
Return on Equity
-850.81%
Trailing 12-Months
Asset Growth
-17.74%
Trailing 12-Months
Company Description
Humacyte
Alpha Healthcare Acquisition Corp is a blank check company.
---
HUMA Earnings Call
Q3 2024
0:00 / 0:00
---
HUMA Stock 12 Month Forecast
Average Price Target
$13.00
▲(124.91% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+23.40%
reiterated a buy rating last month
Copying Bruce Jackson's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +23.40% per trade.
---